RUNX1 and acute myeloid leukemia: The German–Austrian AML Study Group (AMLSG) has demonstrated correlations of RUNX1–RUNX1T1 levels after chemotherapies with KIT mutations (exons 17 and/or 8), with KIT-unmutated patients achieving deeper MRD reductions at the end of treatment [10].